Renaissance Technologies LLC decreased its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 481,462 shares of the biopharmaceutical company’s stock after selling 1,008 shares during the period. Renaissance Technologies LLC’s holdings in Regeneron Pharmaceuticals were worth $166,100,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of REGN. Ostrum Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $108,000. Summit Trail Advisors LLC boosted its position in Regeneron Pharmaceuticals by 22,971.8% in the first quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 165,627 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $211,000. Sawtooth Solutions LLC purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $218,000. Finally, Greenleaf Trust purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $231,000. Institutional investors and hedge funds own 66.90% of the company’s stock.
Regeneron Pharmaceuticals stock opened at $406.94 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.92 and a current ratio of 3.62. Regeneron Pharmaceuticals Inc has a 12 month low of $281.89 and a 12 month high of $503.33. The company has a market capitalization of $43.95 billion, a price-to-earnings ratio of 24.71, a P/E/G ratio of 1.36 and a beta of 1.23.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The business had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the firm posted $4.17 EPS. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 19.4 earnings per share for the current year.
REGN has been the topic of a number of recent research reports. Canaccord Genuity reiterated a “$367.74” rating and issued a $304.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, July 19th. TheStreet upgraded Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, July 25th. BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Argus upped their target price on Regeneron Pharmaceuticals from $383.00 to $415.00 and gave the company a “buy” rating in a research report on Monday, July 16th. Finally, Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $370.00 to $396.00 and gave the company an “equal weight” rating in a research report on Friday, July 13th. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $418.04.
In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 121,601 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $309.31, for a total value of $37,612,405.31. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman P Roy Vagelos sold 74,710 shares of the company’s stock in a transaction that occurred on Thursday, June 21st. The stock was sold at an average price of $327.87, for a total value of $24,495,167.70. Following the completion of the sale, the chairman now owns 553,121 shares in the company, valued at approximately $181,351,782.27. The disclosure for this sale can be found here. In the last 90 days, insiders sold 276,481 shares of company stock worth $91,578,625. Insiders own 12.42% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: Momentum Indicator: Relative Strength Index
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.